• HOME
  • CONTACT US
Logo Logo Logo Logo Logo
  • Who We Are
    • Our Story
    • Corporate History
    • Stock Price History
    • Settlement Key Features
    • Growth Strategy
    • Our Patents
  • Leadership
    • Management
    • Board of Directors
    • Committees
  • Pipeline
    • OVERVIEW
    • BASAL CELL CARCINOMA NEVUS SYNDROME
      • WHAT IS BCCNS
      • BCCNS’ UNMET NEED
      • HH INHIBITION WITH ITRACONAZOLE
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • LUNG CANCER
      • NON-SMALL CELL LUNG CANCER
      • ITRACONAZOLE IN NSCLC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • PROSTATE CANCER
      • METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER
      • ITRACONAZOLE IN mCRPC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
  • Investors & Media
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
      • Interactive Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Fundamentals
      • Annual Reports & Proxy Statements
    • Corporate Governance
      • Documents and Charters
      • Committee Composition
    • Investor Resources
  • Who We Are
    • Our Story
    • Corporate History
    • Stock Price History
    • Settlement Key Features
    • Growth Strategy
    • Our Patents
  • Leadership
    • Management
    • Board of Directors
    • Committees
  • Pipeline
    • OVERVIEW
    • BASAL CELL CARCINOMA NEVUS SYNDROME
      • WHAT IS BCCNS
      • BCCNS’ UNMET NEED
      • HH INHIBITION WITH ITRACONAZOLE
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • LUNG CANCER
      • NON-SMALL CELL LUNG CANCER
      • ITRACONAZOLE IN NSCLC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
    • PROSTATE CANCER
      • METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER
      • ITRACONAZOLE IN mCRPC
      • CLINICAL TRIALS & RESULTS
      • FORWARD LOOKING
  • Investors & Media
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
      • Interactive Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Fundamentals
      • Annual Reports & Proxy Statements
    • Corporate Governance
      • Documents and Charters
      • Committee Composition
    • Investor Resources
Notice of Proposed Settlement of Stockholder Litigation. Click here for information.
Search:
 

SEC Filings

OTCQB: INTI
PRICE:
Stock Info
OTCQB: INTIOTCQB: HPPI
OTCQB: INTIOTCQB: HPPI
YearCalendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014Calendar Year 2013Calendar Year 2012Calendar Year 2011Calendar Year 2010Calendar Year 2009Calendar Year 2008Calendar Year 2007Calendar Year 2006Calendar Year 2005Calendar Year 2004Calendar Year 2003Calendar Year 2002Calendar Year 2001Calendar Year 2000Calendar Year 1999Calendar Year 1998Calendar Year 1997
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Mergers & AcquisitionsProxy & Information StatementsOther
FormDescriptionDateFormat
Get Important News and Updates by Email
* Required Fields
Inhibitor-Therapeutics

4905 Westshore Blvd.
Tampa, FL 33611

Our Mission

Inhibitor Therapeutics, Inc. (“INHIBITOR”) is a pharmaceutical development company focused on developing and commercializing innovative therapies based on already approved active pharmaceutical ingredients for novel, clinically valuable, and patent-protected indications. Our lead product is itraconazole for a hereditary, cancer syndrome (Gorlin’s syndrome) which is an orphan disease.

  • Home
  • Who We Are
  • Pipeline
  • Investors & Media
  • Contact Us
  • Terms of Use and Privacy Policy

Copyright 2023 Inhibitor Therapeutics, Inc.